Filing Flows › Incyte (INCY) › Guidance & outlook
Incyte (INCY) guidance and outlook
Incyte (INCY) raised some and lowered other parts of its guidance on Oct 29, 2026: Revenue $1.1B for FY2026; Operating expenses $4.6B–$4.7B for FY2026. Incyte's 10-Q filed Jul 28, 2026 makes 23 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.1B | lowered |
| Operating expenses | FY2026 | $4.6B–$4.7B | reaffirmed |
From the earnings release filed Oct 29, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Jul 28, 2026
- • our collaboration and strategic relationship strategy, and anticipated benefits and disadvantages of entering into collaboration agreements;
- • our licensing, investment and commercialization strategies, including our plans to commercialize our drug products and drug candidates;
- • the timing, structure and size of our clinical trials; the compounds expected to enter clinical trials; the nature and timing of clinical trial results;
- • plans to develop and commercialize products on our own;
- • our ability to obtain, or maintain at anticipated levels, coverage and reimbursement for our products from government health administration authorities, private health insurers and other organizations;
- • If we or our collaborators are unable to obtain, or maintain at anticipated levels, coverage and reimbursement for our products from government health administration authorities, private health insurers and other organizations, our pricing may be affected and our product sales, results of operations and financial condition could be harmed.
- • If we are unable to establish and maintain effective sales, marketing and distribution capabilities, or to enter into agreements with third parties to do so, we will not be able to successfully commercialize our products.
- • We may incur losses in the future, and we expect to continue to incur significant expenses to discover and develop drugs, which may make it difficult for us to achieve sustained profitability on a quarterly or annual basis in the future.
- Following a comprehensive review of available data, we discontinued further development of INCB160058 to prioritize our next-generation JAK2V617F-targeted pipeline.
- We anticipate a regulatory decision from the European Commission in the third quarter of 2026.
- We submitted an MAA for povorcitinib to the EMA at the end of 2025 and we anticipate a potential approval in late 2026.
- The NDA submission for povorcitinib in HS was accepted by the FDA in the first quarter of 2026 and we anticipate a potential approval in the U.S. by the first quarter of 2027.
Incyte's latest quarter
Incyte, Q3 2026: revenue $1.6B (+14% year over year), operating margin -45.5%, net loss $785M, operating cash flow −$675M. The chart follows the revenue to costs, profit and cash.
Questions
Did Incyte raise or lower its guidance?
Incyte (INCY) raised some and lowered other parts of its guidance on Oct 29, 2026: Revenue $1.1B for FY2026; Operating expenses $4.6B–$4.7B for FY2026.
What does Incyte expect?
• our collaboration and strategic relationship strategy, and anticipated benefits and disadvantages of entering into collaboration agreements; • our licensing, investment and commercialization strategies, including our plans to commercialize our drug products and drug candidates; • the timing, structure and size of our clinical trials; the compounds expected to enter clinical trials; the nature and timing of clinical trial results;
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.